Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Beta-lactam + beta-lactamase inhibitor antibiotic

Co-amoxiclav 625mg (Augmentin)

Brand names: Augmentin

Used in: Sepsis Pneumonia Urinary Tract Infection Cellulitis & Skin Infection

Co-amoxiclav combines amoxicillin with clavulanic acid and is used for infections likely to involve beta-lactamase–producing bacteria, including some ENT, respiratory, urinary and skin infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Amoxicillin inhibits bacterial cell-wall synthesis; clavulanic acid inhibits beta-lactamase enzymes, restoring activity against many resistant organisms.

Prescribing in practice

  • Reserve it for indications where added beta-lactamase cover is needed, to limit resistance and adverse effects.
  • It carries a higher risk of cholestatic hepatitis (especially in older patients and with prolonged courses) and of diarrhoea than amoxicillin alone.
  • Contraindicated in penicillin allergy and in a history of co-amoxiclav–associated jaundice/hepatic dysfunction.

Monitoring

Short courses need no routine monitoring; consider liver function with prolonged or repeated use.

Counselling the patient

  • Complete the course; take it with food to reduce stomach upset.
  • Report a rash, yellowing of the skin or eyes, or severe diarrhoea.

Evidence & guidelines

Used per local antimicrobial guidance where beta-lactamase cover is required.

Reference: NICE NG98 AOM; NICE NG120 Sinusitis; PHE Antibiotic Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways